<p>Through clinical trials focused on molecularly guided therapy in pediatric cancers (<a href="https://clinicaltrials.gov/ct2/show/NCT01355679">NCT01355679</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT01802567">NCT01802567</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT02162732">NCT02162732</a>), the Beat Childhood Cancer Consortium performed paired tumor/normal whole exome sequencing and/or tumor mRNA sequencing for 202 pediatric or adolescent young adult patients with rare, relapsed and refractory cancers (including neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, ependymoma, glioma, and other rare solid tumors). A subset of these patients had multiple biopsies sequenced, including longitudinal profiling.</p>

Genomic Profiling of Relapsed and Refractory Childhood Cancers

14 variables across Demographics, Race and Ethnicity

Genomic Profiling of Relapsed and Refractory Childhood Cancers

Demographics (3)

Race and Ethnicity (1)

Other (10)